Skip to main content
Premium Trial:

Request an Annual Quote

Aurora Completes Acquisition of Panvera

NEW YORK, March 1 - Aurora Biosciences said Thursday it completed its acquisition of Panvera, a Madison, Wisc.-based manufacturer of recombinant protein drug targets and protein drug screening assays.

Under the terms of the agreement, which has been approved by Panvera shareholders, Aurora will issue up to 1.9 million shares of its common stock in the transaction.

On November 17, the day the deal was originally announced, Aurora’s stock was trading just above $45 a share. Since then, the price has steadily fallen to about $18 a share.

Aurora Biosciences of San Diego develops and applies proprietary technologies to accelerate the discovery of new medicines.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.